329aefd4ef555a02…

{
  "id": "NCT00104273",
  "type": "Study",
  "data": {
    "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.",
    "completionDate": null,
    "conditions": [
      "Dementia",
      "Alzheimer's Disease"
    ],
    "enrollmentCount": 376,
    "enrollmentType": "ACTUAL",
    "nctId": "NCT00104273",
    "phase": "PHASE2",
    "sponsorId": "teva-branded-pharmaceutical-products-r-d-inc",
    "startDate": "2004-08",
    "status": "COMPLETED",
    "studyType": "INTERVENTIONAL",
    "title": "A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type",
    "url": "https://clinicaltrials.gov/study/NCT00104273"
  }
}